We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Mindray Launches High Throughput BS-600M Chemistry Analyzer with Industry-Leading Small Footprint

By LabMedica International staff writers
Posted on 16 May 2022
Print article
Image: The new BS-600M chemistry analyzer provides a complete package to help labs grow (Photo courtesy of Mindray)
Image: The new BS-600M chemistry analyzer provides a complete package to help labs grow (Photo courtesy of Mindray)

Mindray (Shenzhen, China) has launched the new BS-600M, a powerful yet efficient chemistry analyzer designed to empower medium-volume laboratories with increased productivity, efficiency and reliability.

With a compact footprint of only 1.2 square meters and a throughput of 600 T/H (up to 800 T/H with ISE), the BS-600M chemistry analyzer has among the highest levels of throughput per square meter. It maximizes productivity for laboratories in a minimum amount of space. BS-600M allows continuous sample loading by racks and flexible STAT priority, which enables higher efficiency and prolonged walk-away time. Having high Sigma metric performance, it can help laboratories deliver high levels of testing quality, reduce QC measurements, simplify QC rules, and shorten turn-around time. These advantages enable significant reductions in troubleshooting work and consumption of QCs and reagents.

BS-600M features on-board hemolysis with whole blood for HbA1c tests. This eliminates the need for manual pretreatment, improving testing efficiency and reducing biohazardous risks and human errors. Mindray’s HbA1c assay on BS-600M can achieve excellent accuracy and precision. The enzymatic HbA1c method can also effectively prevent interferences from Hb variants and ensure no interference from other Hb derivatives. This means that reliable results can be obtained at the first measurement, without requiring further confirmations. Additionally, BS-600M requires much reduced reaction volumes for HbA1c tests, which contributes to around 30% lower cost per test. BS-600M also integrates a brand-new ISE solution, which reduces both the frequency of electrode replacement and the consumption of ISE reagents. As the result, the cost per test for ISE is reduced by around 35%. Moreover, ISE tests on BS-600M exhibit top levels of accuracy and precision in the field of ISE detection.

BS-600M also incorporates several other powerful functions, including intelligent detection, alarming and auto-rerun of abnormal reactions, fast input of QC & CAL target values via barcode scanning, a user-friendly operation interface, and breathing LEDs that indicate the status of the analyzer. All these powerful functions allow BS-600M to help medium-sized laboratories maximize their working efficiency and cost efficiency, and provide an amazing user experience for laboratory technicians. The performance advantages of BS-600M allow it to offer highly reliable results at reduced costs and to enhance clinician confidence and satisfaction.

Related Links:
Mindray 

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Systemic Autoimmune Testing Assay
BioPlex 2200 ANA Screen with MDSS

Print article

Channels

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Microbiology

view channel
Image: The ePlex system has been rebranded as the cobas eplex system (Photo courtesy of Roche)

Enhanced Rapid Syndromic Molecular Diagnostic Solution Detects Broad Range of Infectious Diseases

GenMark Diagnostics (Carlsbad, CA, USA), a member of the Roche Group (Basel, Switzerland), has rebranded its ePlex® system as the cobas eplex system. This rebranding under the globally renowned cobas name... Read more

Pathology

view channel
Image: The revolutionary autonomous blood draw technology is witnessing growing demands (Photo courtesy of Vitestro)

Robotic Blood Drawing Device to Revolutionize Sample Collection for Diagnostic Testing

Blood drawing is performed billions of times each year worldwide, playing a critical role in diagnostic procedures. Despite its importance, clinical laboratories are dealing with significant staff shortages,... Read more